ocrevus | Media Room | PressRelease.com

Tagged ocrevus

Genentech's Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists

Press Release Sep 19, 2018

Genentech's Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists

Unaided awareness of EMD Serono's Mavenclad (cladribine tablets) and Novartis' siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate the newest agents into their multiple sclerosis armamentarium, according to a new report from Spherix Global Insights Read More

First
Prev

1

Next
Last